Modified single-stranded oligonucleotides inhibit aggregate formation and toxicity induced by expanded polyglutamine

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Huntington's disease (HD) is a neurodegenerative disorder caused by an expanded polyglutamine (poly(Q)) tract in the huntingtin (Htt) protein.
• Htt protein aggregation into inclusions is a key pathological hallmark of HD.
• Therapeutic strategies aim to block the nucleation or elongation phases of Htt aggregation.

Purpose of the Study:

• To investigate the potential of modified single-stranded oligonucleotides to inhibit Htt aggregation.
• To identify specific oligonucleotide characteristics that confer inhibitory activity.
• To evaluate the therapeutic potential of these oligonucleotides in a cellular model of HD.

Main Methods:

• Utilized a cell-based assay with a model neuronal cell line to assess the inhibition of Htt inclusion formation.
• Employed a standardized biochemical assay to identify disruptive molecules.
• Tested various modified oligonucleotides, including different lengths and phosphorothioate modifications.
• Assessed the impact of active oligonucleotides on PC12 cell lifespan post-Htt aggregation induction.

Main Results:

• Modified single-stranded oligonucleotides effectively retarded Htt inclusion formation.
• Oligonucleotide activity was dependent on chemical modifications rather than sequence specificity.
• Certain active oligonucleotides extended the lifespan of PC12 cells affected by Htt aggregation.

Conclusions:

• Short synthetic oligonucleotides represent a novel therapeutic approach for Huntington's disease.
• These oligonucleotides inhibit a fundamental pathological pathway in HD.
• Further research into modified oligonucleotides could lead to effective HD treatments.